BRPI0414072A - composição farmacêutica e seus usos para o retardo de doenças cardiovasculares - Google Patents

composição farmacêutica e seus usos para o retardo de doenças cardiovasculares

Info

Publication number
BRPI0414072A
BRPI0414072A BRPI0414072-9A BRPI0414072A BRPI0414072A BR PI0414072 A BRPI0414072 A BR PI0414072A BR PI0414072 A BRPI0414072 A BR PI0414072A BR PI0414072 A BRPI0414072 A BR PI0414072A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
cardiovascular disease
retardation
magnesium
green tea
Prior art date
Application number
BRPI0414072-9A
Other languages
English (en)
Inventor
Matthias Rath
Aleksandra Niedzwiecki
Vadim Ivanov
Waheed M Roomi
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/657,019 external-priority patent/US20050053673A1/en
Application filed by Matthias Rath filed Critical Matthias Rath
Publication of BRPI0414072A publication Critical patent/BRPI0414072A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA E SEUS USOS PARA O RETARDO DE DOENçAS CARDIOVASCULARES". A presente invenção fornece composições farmacêuticas que compreendem lisina, prolina, arginina, vitamina C, magnésio, extrato de chá verde, N-acetil-cisteína, selênio, cobre, manganês e um componente farmacêutico aceitável selecionado do grupo que consiste em um transportador, um diluente e um excipiente, onde a composição farmacêutica sem o componente aceitável contém 7-9% em peso de magnésio, 20-30% em peso de ácido ascórbico e 11-25% em peso extrato de chá verde. Um método de tratamento de doença cardiovascular que usa as composições farmacêuticas também é revelado, mais preferivelmente para o tratamento de mulheres na pós-menopausa.
BRPI0414072-9A 2003-09-05 2004-08-18 composição farmacêutica e seus usos para o retardo de doenças cardiovasculares BRPI0414072A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/657,019 US20050053673A1 (en) 2003-09-05 2003-09-05 Composition and method for facilitating bone healing
US10/801,262 US20050053674A1 (en) 2003-09-05 2004-03-15 Pharmaceutical composition and method for retardation of the progression of atherosclerosis
PCT/EP2004/009263 WO2005023239A1 (en) 2003-09-05 2004-08-18 Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases

Publications (1)

Publication Number Publication Date
BRPI0414072A true BRPI0414072A (pt) 2006-10-24

Family

ID=34279085

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414072-9A BRPI0414072A (pt) 2003-09-05 2004-08-18 composição farmacêutica e seus usos para o retardo de doenças cardiovasculares

Country Status (10)

Country Link
EP (1) EP1689381B1 (pt)
JP (1) JP2008509877A (pt)
KR (1) KR20060069850A (pt)
AU (1) AU2004269872A1 (pt)
BR (1) BRPI0414072A (pt)
CA (1) CA2532161A1 (pt)
MX (1) MXPA06002534A (pt)
PL (1) PL1689381T3 (pt)
RU (1) RU2006110952A (pt)
WO (1) WO2005023239A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062415A1 (en) * 2005-11-26 2007-05-31 Grinrx Corporeal delivery of carotenoids
JP5151083B2 (ja) * 2006-07-20 2013-02-27 大正製薬株式会社 経口用組成物
KR101671959B1 (ko) * 2012-03-07 2016-11-03 주식회사 케어사이드 심장 및 간 기능 개선용 조성물 및 이를 포함하는 기능성 식품
JP6347956B2 (ja) * 2014-01-17 2018-06-27 ポーラ化成工業株式会社 経口用組成物
WO2019117702A1 (en) * 2017-12-16 2019-06-20 Kam Faii Yuen A medicament to control and reduce hypertension

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5862117A (ja) * 1981-10-07 1983-04-13 Yoshihiro Futsusa 抗動脈硬化剤
JPH0656686A (ja) * 1992-08-04 1994-03-01 Itouen:Kk 抗動脈硬化剤
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
US5849337A (en) * 1997-06-27 1998-12-15 Gusty Winds Corporation Method of enhancing magnesium absorption and prevention of atherosclerosis
EP1210079A2 (en) * 1999-08-20 2002-06-05 Ferrosan A/S A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
JP2005519055A (ja) 2002-01-11 2005-06-30 ラート・マティアス ポリフェノール類を含む栄養医薬製剤および癌の治療におけるその使用方法（関連出願の説明）本願は、２００２年１月１１日に出願された米国仮特許出願第６０／３４８，１４３号の、米国特許法第１１９条（ｅ）に基づく利益を主張し、その内容は参照によりそのまま本明細書に組み込まれるものとする。

Also Published As

Publication number Publication date
EP1689381B1 (en) 2010-02-24
RU2006110952A (ru) 2006-08-27
JP2008509877A (ja) 2008-04-03
WO2005023239A1 (en) 2005-03-17
CA2532161A1 (en) 2005-03-17
MXPA06002534A (es) 2006-06-20
AU2004269872A1 (en) 2005-03-17
EP1689381A1 (en) 2006-08-16
PL1689381T3 (pl) 2010-07-30
KR20060069850A (ko) 2006-06-22

Similar Documents

Publication Publication Date Title
NO20061461L (no) Farmasoytisk sammensetning som blant annet omfatter vitamin C, magnesium og ekstrakt av gronn te for hemming av hjertekarsykdommer
NO20060143L (no) Farmasoytisk preparat og fremgangsmate for a lindre bivirkninger av ostrogenerstatningsbehandling
Jara-Palacios et al. Assessment of white grape pomace from winemaking as source of bioactive compounds, and its antiproliferative activity
Hernandez-Ceruelos et al. Inhibitory effect of chamomile essential oil on the sister chromatid exchanges induced by daunorubicin and methyl methanesulfonate in mouse bone marrow
Liu et al. Antioxidant activity and phenolic compounds of Holotrichia parallela Motschulsky extracts
RU2007111720A (ru) Активаторы митохондрий
Shanmugapriya et al. Antioxidant activity, total phenolic and flavonoid contents of Artocarpus heterophyllus and Manilkara zapota seeds and its reduction potential
BRPI0507593A (pt) composições contendo cis-isÈmeros de um composto carotenóide e processo
RU2004124384A (ru) Обладающий питательными свойствами фармацевтический состав на основе полифенолов и его использование при лечении рака
JP2009543756A (ja) 抗酸化活性が改善された微量養分を含有する組成物及びその使用
MX2007013623A (es) Preparacion externa para la piel.
WO2003086329A8 (en) Skincare compositions comprising anti-oxidant agents
Martínez-Busi et al. Purification, structural elucidation, antioxidant capacity and neuroprotective potential of the main polyphenolic compounds contained in Achyrocline satureioides (Lam) DC (Compositae)
NO20076682L (no) Nye pyridinanaloger
Silvia et al. Novel molecular combination deriving from natural aminoacids and polyphenols: Design, synthesis and free-radical scavenging activities
Nabavi et al. Neuroprotective effects of silymarin on sodium fluoride-induced oxidative stress
Tocmo et al. Organosulfide profile and hydrogen sulfide-releasing capacity of stinky bean (Parkia speciosa) oil: Effects of pH and extraction methods
de Almeida et al. Phenolic compounds of Triplaris gardneriana can protect cells against oxidative stress and restore oxidative balance
HUP0300732A2 (hu) Chlamydiás fertżzések kezelésében és megelżzésében hatékony növényi-eredetż és szintetikus fenolos vegyületek és növényi extraktumok
BRPI0414072A (pt) composição farmacêutica e seus usos para o retardo de doenças cardiovasculares
Ogunleye et al. Chenopodium ambrosioides var. ambrosioides leaf extracts possess regenerative and ameliorative effects against mercury-induced hepatotoxicity and nephrotoxicity
Torre et al. Evaluation of antioxidant capacity and identification of bioactive compounds of crude methanol extracts of Caesalpinia pulcherrima (L.) Swartz
AR025790A1 (es) Composicion para la prevencion y/o tratamiento de desordenes circulatorios, que comprende derivados de l-carnitina y extractos de ginkgo biloba
Sabir et al. Antioxidant properties of β-seleno amines against lipid peroxidation in rat brain and liver
TW200715997A (en) Method for prevention of formation of abnormal odor in beverage composition

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 45/06 (2006.01), A61K 31/198 (2006.01), A61K